170 related articles for article (PubMed ID: 10718341)
1. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
2. 5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.
Jaffar M; Naylor MA; Robertson N; Lockyer SD; Phillips RM; Everett SA; Adams GE; Stratford IJ
Anticancer Drug Des; 1998 Mar; 13(2):105-23. PubMed ID: 9524554
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase.
Phillips RM
Biochem Pharmacol; 1996 Dec; 52(11):1711-8. PubMed ID: 8986133
[TBL] [Abstract][Full Text] [Related]
4. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression.
Smitskamp-Wilms E; Peters GJ; Pinedo HM; van Ark-Otte J; Giaccone G
Biochem Pharmacol; 1994 Apr; 47(8):1325-32. PubMed ID: 7514407
[TBL] [Abstract][Full Text] [Related]
6. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
7. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
8. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
Smitskamp-Wilms E; Giaccone G; Pinedo HM; van der Laan BF; Peters GJ
Br J Cancer; 1995 Oct; 72(4):917-21. PubMed ID: 7547240
[TBL] [Abstract][Full Text] [Related]
9. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs.
Phillips RM; Jaffar M; Maitland DJ; Loadman PM; Shnyder SD; Steans G; Cooper PA; Race A; Patterson AV; Stratford IJ
Biochem Pharmacol; 2004 Dec; 68(11):2107-16. PubMed ID: 15498501
[TBL] [Abstract][Full Text] [Related]
11. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
Kim JY; Patterson AV; Stratford IJ; Hendry JH
Anticancer Drugs; 2004 Jan; 15(1):71-7. PubMed ID: 15090746
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.
Danson SJ; Johnson P; Ward TH; Dawson M; Denneny O; Dickinson G; Aarons L; Watson A; Jowle D; Cummings J; Robson L; Halbert G; Dive C; Ranson M
Ann Oncol; 2011 Jul; 22(7):1653-1660. PubMed ID: 21378203
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.
Robertson N; Haigh A; Adams GE; Stratford IJ
Eur J Cancer; 1994; 30A(7):1013-9. PubMed ID: 7946565
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
15. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
[TBL] [Abstract][Full Text] [Related]
16. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
17. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
18. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
Collard J; Matthew AM; Double JA; Bibby MC
Br J Cancer; 1995 Jun; 71(6):1199-203. PubMed ID: 7779711
[TBL] [Abstract][Full Text] [Related]
19. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
20. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
Walton MI; Smith PJ; Workman P
Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
